Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression

NCT: NCT07528157 · NOT_YET_RECRUITING

NCT IDNCT07528157
StatusNOT_YET_RECRUITING
Start Date2026-06-01
Completion2027-12-31

Brief Summary

This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual. A type of brain signal measured with electroencephalography (EEG) after a single pulse of brain stimulation, called an early local TMS-evoked potential (EL-TEP), is used to identify which stimulation settings work best for each participant. The investigators will compare individualized (personalized) iTBS settings to standard (non-personalized) settings and to inactive (sham) stimulation. Participants are adults with treatment-resistant depression.

Frequently Asked Questions

What is Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression?

Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression is a clinical trial registered under NCT07528157. Current status: NOT_YET_RECRUITING.

What is the status of NCT07528157?

The current status of NCT07528157 (Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression) is: NOT_YET_RECRUITING.

When did Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression start?

Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression started on 2026-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑